HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Glycerylphosphorylcholine (Choline Alfoscerate)

A component of PHOSPHATIDYLCHOLINES or LECITHINS, in which the two hydroxy groups of GLYCEROL are esterified with fatty acids. (From Stedman, 26th ed)
Also Known As:
Choline Alfoscerate; Choline Alphoscerate; Glycerol 3-Phosphocholine; Glycerophosphorylcholine; L-alpha-Glycerylphosphorylcholine; 3-Phosphocholine, Glycerol; Alfoscerate, Choline; Alphoscerate, Choline; Glycerol 3 Phosphocholine; Glycerophosphate, Choline; L alpha Glycerylphosphorylcholine; Choline Glycerophosphate; Ethanaminium, 2-(((2,3-dihydroxypropoxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, inner salt
Networked: 109 relevant articles (8 outcomes, 22 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Amenta, Francesco: 10 articles (01/2022 - 10/2002)
2. Traini, Enea: 6 articles (01/2022 - 06/2007)
3. Tomassoni, Daniele: 5 articles (02/2013 - 10/2002)
4. Carotenuto, Anna: 4 articles (01/2022 - 11/2012)
5. Fasanaro, Angiola Maria: 4 articles (01/2022 - 11/2012)
6. Rea, Raffaele: 3 articles (01/2017 - 11/2012)
7. Boros, Mihály: 3 articles (01/2016 - 01/2013)
8. Amenta, F: 3 articles (01/2008 - 11/2001)
9. Han, Su-Hyun: 2 articles (08/2022 - 06/2018)
10. Manzo, Valentino: 2 articles (01/2022 - 01/2017)

Related Diseases

1. Dementia (Dementias)
2. Cognitive Dysfunction
3. Stroke (Strokes)
4. Alzheimer Disease (Alzheimer's Disease)
5. Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy)
07/01/1991 - "A multicentre trial to evaluate the efficacy and tolerability of alpha-glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia."
03/01/2020 - "CONIVaD (choline alphoscerate and nimodipine in vascular dementia) is a pilot, single-center, double-blinded, randomized trial aimed to assess whether the association of choline alphoscerate and nimodipine is more effective than nimodipine alone in reducing cognitive decline in patients with SVD and mild-to-moderate cognitive impairment. "
01/01/2021 - "The CONIVaD (Choline Alphoscerate and Nimodipine in Vascular Dementia) study aimed to investigate the feasibility, efficacy, and safety of a combined treatment with choline alphoscerate and nimodipine in patients with SVD and mild-to-moderate cognitive impairment. "
07/01/1991 - "An open clinical trial was carried out to compare the efficacy and the tolerability of 1 g/day alpha-glycerylphosphorylcholine (alpha-GPC) with 1 g/day cytosine diphosphocholine (CDP) both given intramuscularly for 90 days in 120 patients with mild to moderate vascular dementia. "
11/01/2001 - "Thirteen published clinical trials, examining in total 4054 patients, have evaluated the use of choline alphoscerate in various forms of dementia disorders of degenerative, vascular or combined origin, such as senile dementia of the Alzheimer's type (SDAT) or vascular dementia (VaD) and in acute cerebrovascular diseases, such as transitory ischemic attack (TIA) and stroke. "

Related Drugs and Biologics

1. Acetylcholine (Acetylcholine Chloride)
2. Glycerylphosphorylcholine (Choline Alfoscerate)
3. Cholinergic Agents (Cholinergics)
4. Choline (Choline Chloride)
5. Nimodipine (Modus)
6. Succinic Acid (Succinate)
7. Cytidine Diphosphate Choline (Citicoline)
8. Cholinesterase Inhibitors (Anticholinesterases)
9. Donepezil (Aricept)
10. Phosphorylcholine (Phosphocholine)

Related Therapies and Procedures

1. Aftercare (After-Treatment)
2. Therapeutics
3. Hepatectomy
4. Anesthesia